phone: 785-296-2436 fax: 785-296-0231 steve.anderson@budget.ks.gov

Steven J. Anderson, CPA, MBA, Director

Division of the Budget

Sam Brownback, Governor

February 21, 2011

The Honorable Roger Reitz, Chairperson Senate Committee on Local Government Statehouse, Room 223-E Topeka, Kansas 66612

Dear Senator Reitz:

SUBJECT: Fiscal Note for SB 131 by Senate Committee on Public Health and

Welfare

In accordance with KSA 75-3715a, the following fiscal note concerning SB 131 is respectfully submitted to your committee.

SB 131 would amend current law by removing ephedrine and pseudoephedrine from the schedule V list of drugs and adding them to the schedule III list of controlled substances. Ephedrine and pseudoephedrine can be used as precursors for the manufacture of methamphetamine. Under existing law, dispensation of schedule III drugs requires a prescription from a medical practitioner.

The Kansas Sentencing Commission estimates that passage of SB 131 would result in an increase of up to three adult prison beds in FY 2012 and an increase of up to four adult prison beds by FY 2021. Currently, the number of male inmates exceeds the available bed capacity of 8,259, and based upon the Kansas Sentencing Commission projections, it is estimated that at the end of FY 2011 and FY 2012, the number of male inmates will exceed available capacity by 235 beds and 394 beds, respectively. To address capacity issues, the Governor's recommended FY 2012 budget includes \$2.5 million for contract prison beds. If it is determined that facility construction is necessary, the Department of Corrections has identified two capacity expansion projects: two high medium security housing units at El Dorado Correctional Facility that would provide 512 beds with a construction cost of \$22,687,232 (\$44,311 per bed X 512) and operating costs of \$9,339,904 (\$18,242 per bed X 512); and one minimum security housing unit at Ellsworth Correctional Facility that would provide 100 beds with a construction cost of \$5,935,000 (\$59,350 per bed X 100) and operating costs of \$1,832,000 (\$18,320 per bed X 100).

Enactment of SB 131 would have no fiscal effect on the Board of Pharmacy. Currently, the Board tracks all schedule III prescription drugs through the agency's monitoring program, K-

The Honorable Roger Reitz, Chairperson February 21, 2011 Page 2—Fisc_Note_Sb131

Tracs. The substances added to the schedule under the new bill would be included in the tracking process without affecting Board workloads. Any fiscal effect associated with SB 131 is not reflected in *The FY 2012 Governor's Budget Report*.

Sincerely,

Steven J. Anderson, CPA, MBA

Director of the Budget

cc: Debra Billingsley, Pharmacy